Suppr超能文献

微纤溶酶的实验评估——活性染料的替代品

Experimental evaluation of microplasmin - an alternative to vital dyes.

作者信息

Gandorfer Arnd

机构信息

Vitreoretinal and Pathology Unit, Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany.

出版信息

Dev Ophthalmol. 2008;42:153-159. doi: 10.1159/000139004.

Abstract

Complete separation of the vitreous from the retina is a major goal of vitrectomy. Mechanical vitrectomy, however, is not able to meet this need because remnants of the vitreous cortex are left behind at the retinal surface, resulting in incomplete posterior vitreous detachment (PVD). As incomplete PVD and an attached vitreous cortex are associated with the progression of common retinal diseases including diabetic retinopathy and maculopathy, central retinal vein occlusion, and proliferative vitreoretinopathy, induction of complete PVD is a major issue both in vitreoretinal surgery and in medical retina. This chapter focuses on one of the most promising current concepts of pharmacologic vitreolysis, i.e. microplasmin-assisted vitrectomy. Microplasmin (Thrombogenics Ltd., Dublin, Ireland) is a recombinant molecule consisting of the catalytic domain of human plasmin. It shares the same catalytic properties like human plasmin, but it is much more stable compared to plasmin. It has been shown previously that both plasmin and microplasmin are capable of inducing PVD. Herein, we report on the preclinical work regarding plasmin and microplasmin which led to the clinical investigation of microplasmin.

摘要

玻璃体与视网膜的完全分离是玻璃体切除术的主要目标。然而,机械性玻璃体切除术无法满足这一需求,因为玻璃体皮质的残余物会留在视网膜表面,导致不完全性玻璃体后脱离(PVD)。由于不完全性PVD和附着的玻璃体皮质与包括糖尿病性视网膜病变和黄斑病变、视网膜中央静脉阻塞以及增生性玻璃体视网膜病变在内的常见视网膜疾病的进展相关,诱导完全性PVD是玻璃体视网膜手术和视网膜内科的一个主要问题。本章重点介绍当前最有前景的药物性玻璃体溶解概念之一,即微纤溶酶辅助玻璃体切除术。微纤溶酶(血栓形成有限公司,爱尔兰都柏林)是一种由人纤溶酶催化结构域组成的重组分子。它与人纤溶酶具有相同的催化特性,但与纤溶酶相比更稳定。先前已表明,纤溶酶和微纤溶酶均能够诱导PVD。在此,我们报告关于纤溶酶和微纤溶酶的临床前研究工作,这些工作促成了微纤溶酶的临床研究。

相似文献

1
Experimental evaluation of microplasmin - an alternative to vital dyes.
Dev Ophthalmol. 2008;42:153-159. doi: 10.1159/000139004.
2
Microplasmin-assisted vitrectomy.
Dev Ophthalmol. 2009;44:26-30. doi: 10.1159/000223942. Epub 2009 Jun 3.
3
Enzymatic vitreous disruption.
Eye (Lond). 2008 Oct;22(10):1273-7. doi: 10.1038/eye.2008.29. Epub 2008 Feb 22.
4
Pharmacologic vitreolysis.
Dev Ophthalmol. 2007;39:149-156. doi: 10.1159/000098505.
5
Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy.
Curr Pharm Biotechnol. 2011 Mar 1;12(3):410-22. doi: 10.2174/138920111794480516.
6
Enzymatic vitreolysis.
Curr Diabetes Rev. 2009 Feb;5(1):57-62. doi: 10.2174/157339909787314220.
7
Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes.
Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3295-9. doi: 10.1167/iovs.04-1517.
8
Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial.
Ophthalmology. 2009 Jul;116(7):1349-55, 1355.e1-2. doi: 10.1016/j.ophtha.2009.03.051. Epub 2009 May 17.
9
Pharmacologic vitreolysis in diabetic retinopathy.
Curr Pharm Biotechnol. 2011 Mar 1;12(3):406-9. doi: 10.2174/138920111794480543.
10
Enzymatic Vitrectomy and Pharmacologic Vitreodynamics.
Dev Ophthalmol. 2016;55:357-64. doi: 10.1159/000438962. Epub 2015 Oct 26.

引用本文的文献

1
Physiology of vitreous surgery.
Graefes Arch Clin Exp Ophthalmol. 2009 Feb;247(2):147-63. doi: 10.1007/s00417-008-0980-7. Epub 2008 Nov 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验